Evidence map›Paper›PMID 35154775›Full record

ArticleSAGE open medical case reports2021

Effective management of advanced colon cancer genotyping microsatellite stable/microsatellite instable-low with Kirsten rat sarcoma viral oncogene mutation using nivolumab plus ipilimumab combined with regorafenib and irinotecan: A case report.

Yingqiang Cui, Yimeng Ou, Yongping Luo, Jiongbiao Yu, Yiguang Lin, Size Chen

Open access · goldAbstract readCase Reports
In one paragraph

Article in SAGE open medical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Yingqiang CuiDepartment of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Yimeng OuDepartment of General Surgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Yongping LuoDepartment of General Surgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Jiongbiao YuDepartment of General Surgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Yiguang LinGuangdong Provincial Engineering Research Center for Esophageal Cancer Precise Therapy, Guangdong Pharmaceutical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-4637-9701
Size ChenDepartment of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
First Affiliated Hospital of Guangdong Pharmaceutical University · CNGuangdong Pharmaceutical University · CNUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microsatellite stable /microsatellite instable-low is the most common colorectal cancer genotype, counting for approximately 85% of common colorectal cancer patients. Treatment of advanced microsatellite stable/microsatellite instable-low colorectal cancer is difficult and successful pharmacological treatment options are currently lacking. Here, we report a case of a 37-year-old man with advanced colorectal cancer genotyping microsatellite stable/microsatellite instable-low with a Kirsten rat sarcoma viral oncogene (G12V) mutation. Following palliative surgery, the patient did not response to the common recommended chemotherapy FOLFIRI regimen and other chemotherapy options. Finally, the patient was successfully treated using a unique combinational immunotherapy, using nivolumab plus ipilimumab combined with regorafenib and irinotecan. Significant improvement in the Karnofsky Performance Status scores, liver function and well-being, reduction in serum tumor biomarkers, and reduction in the size of multiple liver metastatic tumors was evident. This report provides a rare case in which a unique and effective combinational immunotherapy for refractory advanced colon cancer patients is discussed. It encourages further research into combined immunotherapy for immuno-insensitive colon cancer patients.

Indexed as

ipilimumabirinotecanMicrosatellite stable/microsatellite instable-low colorectal cancernivolumabregorafenib

Identifiers

PMID35154775
PMCPMC8826103
OpenAlexW3173877037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.